Vitaly Omelyanovsky

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7938047/publications.pdf Version: 2024-02-01



VITALY OMELVANOUSKY

#	Article	IF	CITATIONS
1	Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology, 2021, 26, 4490.	1.4	19
2	Diabetes mellitus as an economic problem in Russian Federation. Diabetes Mellitus, 2016, 19, 30-43.	1.9	17
3	Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871. Farmakoekonomika, 2020, 13, 113-123.	1.2	10
4	Mcda Approach To Ranking Rare Diseases In Russia: Preliminary Results. Value in Health, 2014, 17, A539.	0.3	9
5	Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system. Farmakoekonomika, 2021, 13, 367-376.	1.2	9
6	Concept of value-based healthcare. Farmakoekonomika, 2021, 13, 438-451.	1.2	7
7	The Cost of Melanoma and Kidney, Prostate, and Ovarian Cancers in Russia. Value in Health Regional Issues, 2014, 4, 58-65.	1.2	4
8	Direct Costs of Unintended Pregnancy in the Russian Federation. Applied Health Economics and Health Policy, 2015, 13, 61-68.	2.1	4
9	Evolution of healthcare provider payment mechanisms. Farmakoekonomika, 2020, 12, 318-326.	1.2	3
10	Regulatory framework of the oncological medical care provision. Farmakoekonomika, 2020, 13, 304-315.	1.2	3
11	Main changes in the model of diagnosis-related groups in 2022. Medical Technologies Assessment and Choice (ĐœĐµĐĐֻцĐ,Đ½ÑĐºĐ,е Ñ,еÑĐ½Đ¾Đ»Đ¾Đ³Đ,Đ, ĐžÑ†ĐµĐ½ĐºĐ° Đ, Đ²Ñ‹Đ±Đ¾Ñ€), 2022, 44,	8 ^{0.4}	3
12	MEDICAL CARE FOR HEMORRHOIDS IN THE FEDERAL SUBJECTS OF RUSSIA IN 2018. Koloproktologia, 2020, 19, 126-134.	0.6	2
13	Economic evaluation of therapeutic education (in diabetes school) for patients with type 1 and type 2 diabetes mellitus. Medical Technologies Assessment and Choice (ĐœĐμĐĐ,цĐ,Đ½ŇĐºĐ,Đμ Ñ,ĐμÑĐ½Đ¾Đ»E	ͽϠ҉҈ѢӟѢౢҌ	ϑźÑ†ĐμĐ <mark></mark> ϟ
14	Key business processes in healthcare and their readiness for digital transformation. Medical Technologies Assessment and Choice (ĐœĐμĐĐ,цĐ,Đ½ÑĐºĐ,Đμ Ñ,ĐμÑĐ½Đ¾Đ»Đ¾Đ3Đ,Đ, ĐžÑ†ĐμĐ½ĐºĐ	°Ð,4D2Ñ‹Ð)≟Đ¾Ñ€), 2
15	PRS42 Pharmacoeconomic Analysis of Methylprednisolone Aceponate for Treatment of Atopic Dermatitis and Eczema. Value in Health, 2011, 14, A495.	0.3	1
16	PCN49 Economic Burden of Melanoma in Russia. Value in Health, 2012, 15, A417.	0.3	1
17	Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy. Farmakoekonomika, 2021, 14, 5-15.	1.2	1
18	International experience in determining the cost-effectiveness thresholds. Farmakoekonomika, 2019, 11, 73-80.	1.2	1

#	Article	IF	CITATIONS
19	Organizational structure and funding of health technology assessment agencies around the world. Farmakoekonomika, 2019, 12, 146-154.	1.2	1
20	Health technology assessment and reimbursement of pharmaceuticals in Italy. Farmakoekonomika, 2019, 12, 156-164.	1.2	1
21	Parameters for evaluating the main indicators of coloproctological care in the adult population in the subjects of the far Eastern Federal District in 2016–2018. Farmakoekonomika, 2020, 13, 240-250.	1.2	1
22	The review of the foreign experience on the financing of innovative medical technologies. Farmakoekonomika, 2020, 13, 316-323.	1.2	1
23	Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making. Farmakoekonomika, 2020, 13, 262-269.	1.2	1
24	Cost-effectiveness and budget impact analyses of using implantable cardioverter-defibrillators in the Russian Federation. Farmakoekonomika, 2022, 15, 5-22.	1.2	1
25	PCN53 ANALYSIS OF SOCIOECONOMIC BUREDN OF HEPATOCELLULAR CARCINOMA IN RUSSIA. Value in Health, 2010, 13, A260-A261.	0.3	0
26	PRS21 BURDEN OF BRONCHIAL ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN RUSSIA. Value in Health, 2010, 13, A322.	0.3	0
27	PIN68 Cost- Effectiveness Analysis of Human Papillomavirus Vaccination Program in Russia. Value in Health, 2011, 14, A277-A278.	0.3	0
28	PCV17 Cost-Effectiveness Analysis of Bosentan and Sildenafil Compared with Standard therapy in Treatment of Primary Pulmonary Arterial Hypertension in Russian Federation. Value in Health, 2011, 14, A367.	0.3	0
29	PSS24 Cost-Effectiveness of Ustekinumab vs Etanercept for Severe Psoriasis. Value in Health, 2011, 14, A506.	0.3	0
30	PRS23 Pharmacoeconomic Analysis of Roflumilast for Treatment of Adult Patients With Severe-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD). Value in Health, 2012, 15, A563.	0.3	0
31	PIH12 Burden of Early-Onset Neonatal Sepsis in the Russian Federation. Value in Health, 2012, 15, A538.	0.3	0
32	PCN57 Economic Burden of Prostate Cancer in Russia. Value in Health, 2012, 15, A419.	0.3	0
33	PMS16 Economic Burden of Juvenile Idiopathic Arthritis in Russia. Value in Health, 2012, 15, A442.	0.3	0
34	PUK17 Cost-Mimimization Analysis of Pazopanib Versus Sunitinib, Sorafenib and Bevacizumab+ Interferon á-2a for Patients With Metastatic Renal Cell Carcinoma. Value in Health, 2012, 15, A458.	0.3	0
35	PCN97 Pharmacoeconomic Analysis of the Prostate Cancer Therapy with Gonadotropin-Releasing Hormone Analogues: Leuprorelin, Goserelin, Triptorelin. Value in Health, 2012, 15, A426-A427.	0.3	0
36	Potential Economic Impact of Using Sugammadex for the Routine Reversal of Neuromuscular Blockade in Russian Health Care Setting. Value in Health, 2013, 16, A558-A559.	0.3	0

#	Article	IF	CITATIONS
37	Cost-Minimization Analysis of Maraviroc Versus Darunavir Raltegravir and Enfuvirtide for CCR5-Tropic Treatment-Experienced Patients with HIV Infection in Russia. Value in Health, 2013, 16, A358-A359.	0.3	0
38	Pharmacoeconomic Evaluation of the Fixed-Dose Combination of Abacavir/Lamivudine in the Antiretroviral Therapy of NaÃ ⁻ ve HIV Infected Patients in Russia. Value in Health, 2013, 16, A345-A346.	0.3	0
39	Costs Associated with Cold Chain Used to Store and Transport Thermally Unstable Antiretroviral Drugs. Value in Health, 2013, 16, A360.	0.3	0
40	Comparative Economic Analysis of Retreatment Strategies for HCV Genotype 1 Patients in Russia. Value in Health, 2013, 16, A498.	0.3	0
41	The Cost of Specialized Hospital Care for Patients with Diabetic Foot Ulcers in Russia. Value in Health, 2013, 16, A444.	0.3	0
42	Efficiency Of Rehabilitation Programs For Patients After Traumatic Brain Injury And Acute Cerebrovascular Accident (Stroke) In Russia. Value in Health, 2014, 17, A490.	0.3	0
43	Fixed Dose Combinations of Nucleoside Reverse Transcriptase Inhibitor for NaÃ ⁻ ve Patient with Hiv Infection in Russia: Cost Comparison Analysis. Value in Health, 2014, 17, A669.	0.3	0
44	Cost-Effectiveness Analysis Of Antiviral Pharmacotherapies For Treatment Of Chronic Hepatitis C Virus Infection In Russia. Value in Health, 2014, 17, A366-A367.	0.3	0
45	Estimating the Costs of Drug Supply for Rare Diseases Patients In Russia. Value in Health, 2014, 17, A525.	0.3	0
46	Determination of incremental cost-effectiveness ratios of antitumor drugs. Farmatsiya-Moscow, 2021, 70, 40-45.	0.1	0
47	Development of a method for calculation of demand for medical personnel in the healthcare of the Russian Federation, using a mathematical model. Farmakoekonomika, 2021, 13, 427-437.	1.2	0
48	Organization and financial support of healthcare for public employees in the Russian Federation: a review of departmental health services in the Ministry of Defense. Farmakoekonomika, 2019, 11, 81-91.	1.2	0
49	The health technology assessment system in Australia. Farmakoekonomika, 2020, 12, 333-341.	1.2	0
50	Affordability of in vivo gene therapy. Problems and potential solutions. Farmakoekonomika, 2020, 13, 170-182.	1.2	0
51	Diagnosis-related groups and payments for the treatment of malignant neoplasms in the model of 2019. Farmakoekonomika, 2019, 12, 169-177.	1.2	0
52	Drug provision and health technology assessment in France. Farmakoekonomika, 2020, 13, 71-83.	1.2	0
53	Economic evaluation of providing patients with test strips for blood glucose level monitoring with a frequency indicated in clinical guidelines in the Russian Federation. Medical Technologies Assessment and Choice (ĐœĐμĐĐ,цĐ,Đ½ÑĐºĐ,е Ñ,ĐμÑĐ½Đ¾Đ»Đ¾Đ³Đ,Đ, ĐžÑ†ĐμĐ½Đ®Đ° Đ, Đ2Ñ(Đ±Đ¾Ñ€), 2022,	0.4 , 42.	0
54	Pharmacoeconomic analysis of bronchial asthma prophylaxis in adults and children with allergic rhinitis by means of sublingual allergen-specific immunotherapy. Russian Journal of Allergy, 2021, 18, 5-17.	0.2	0